• Annual revenue up 50% year on year - closing cash of $4.75M
• Strategic partnership formed with Berkeley Biologics LLC to introduce dermal and amniotic tissue product ranges
• Strategic partnership with NetCentrix Ventures for regulatory pathway and future commercialisation in India's US$115M+ nerve repair market

ReNerve Limited (ASX, 'ReNerve' or 'the Company'), an Australian biotechnology company developing innovative products for peripheral nerve injury ('PNI') repair, reported its Quarterly Report for the period ended 30 June 2025 ('Q4 FY25'). The company achieved major milestones during the quarter, with full year sales up 53% compared to the previous year. ReNerve entered a partnership with Berkeley Biologics to develop two new product ranges, anticipated to reach the market in Q3-Q4 CY25. The company also achieved approvals in the Middle East and Asia, and entered a partnership with NetCentrix for the Indian market. During the quarter, sales revenue rose by 25%, resulting in an increase over FY24 of 53%. Cash closed at $4.75M.

The company reported quarterly sales revenue of A$94,000, representing a 25% increase over the previous quarter and contributing to cumulative FY25 sales of A$271,000. ReNerve's net cash position at the end of the quarter was $4.75 million.

ReNerve is well positioned for continued growth, with strategic partnerships to expand its product portfolio and enter new markets, including the US$115M+ nerve repair market in India. The company is focused on progressing its pipeline, including the NervAlign® Nerve Conduit, and driving increased sales of its existing products.